Our finding that SET is frequently overexpressed in NSCLC cancers is novel and suggests that deregulation of SET as a possible contributing mechanism to inhibit PP2A, and overexpression of PP2A inhibitors may play an important role in the development of human NSCLC. This evidence concerns the gene SET and non-small cell lung carcinoma.